Ozempic-like drug fails to treat Parkinson's disease in new study; here's what the scientists said
A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...
The Lancet5d
First phase 3 trial of GLP-1 receptor agonist for neurodegeneration
The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...
GLP-1 drug shows little benefit for people with Parkinson's disease, trial finds
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...
Pharmaceutical Technology19d
Lixisenatide by Sanofi for Parkinson’s Disease: Likelihood of Approval
Lixisenatide is under clinical development by Sanofi and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition ...
The Lancet25d
Movement disorders in 2024: peripheral and outside the box
dGraduate Institute of Biomedical Engineering, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan eGraduate Institute of Molecular Medicine, and Graduate Institute of ...
Hosted on MSN24y
Victoza vs. Ozempic: Which Is Better?
Medically reviewed by Femi Aremu, PharmD Victoza (liraglutide) and Ozempic (semaglutide) are two injectable drugs used to ...